Culligan Announces Launch of Cullie, the First-Ever AI WaterBot
Cullie to advance the water industry through innovative technology aimed at enhancing the customer experience…
Month: June 2023
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…
Curia wins 2023 Frost & Sullivan Customer Value Leadership Award
Curia recognized for providing a best-in-class customer experience in the CRDMO industry through its innovative…
Curia wins 2023 Frost & Sullivan Customer Value Leadership Award
Curia recognized for providing a best-in-class customer experience in the CRDMO industry through its innovative…
Evelo Biosciences Announces Reverse Stock Split Effective
– EVLO common stock expected to begin trading on a split-adjusted basis on June 30,…
Evelo Biosciences Announces Reverse Stock Split Effective
– EVLO common stock expected to begin trading on a split-adjusted basis on June 30,…
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between…
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between…
Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis
– Patient dosing initiated in LUMUS, a 388 patient Phase 2b clinical trial of ESK-001…
Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis
– Patient dosing initiated in LUMUS, a 388 patient Phase 2b clinical trial of ESK-001…
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety…
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety…
Grace Breedingās NFT Bio-Fertilizer Receives its First European Product Registration Approval in Austria for Use in Wheat and Corn
– Grace Breeding’s bio-fertilizer will be marketed under the brand name “Addir™” as a ‘soil…
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
Grace Breedingās NFT Bio-Fertilizer Receives its First European Product Registration Approval in Austria for Use in Wheat and Corn
– Grace Breeding’s bio-fertilizer will be marketed under the brand name “Addir™” as a ‘soil…
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEXāāā against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide…
PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEXāāā against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide…
XORTX Announces Results ofĀ Annual and Special Meeting of Shareholders
CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”)…